Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

This trial is testing whether adding isatuximab (a drug that targets a protein called CD38 on myeloma cells) to lenalidomide maintenance therapy after a stem cell transplant can improve long-term outcomes for people with high-risk multiple myeloma. Multiple myeloma is a cancer of plasma cells in the bone marrow, and high-risk patients are more likely to relapse after standard treatment. **You may be eligible if...** - You are between 18 and 72 years old with newly diagnosed, symptomatic multiple myeloma - Your myeloma is classified as high-risk (based on specific genetic markers or disease features) - You have measurable disease and have been treated prior to transplant - You meet specific blood, protein, and imaging criteria for measurable myeloma **You may NOT be eligible if...** - You do not have high-risk myeloma features - You have had more than one prior stem cell transplant - You have significant organ problems that would make treatment unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.